L & S Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

L & S Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,500	Closed	-$223K	–	399
2021 Q1	$223K	Buy	+12,500	New	+$216K	0.03%	324
2018 Q4	–	Sell	-5,025	Closed	-$309K	–	344
2018 Q3	$309K	Buy	5,025 +200	+4%	+$12.9K	0.04%	257
2018 Q2	$326K	Buy	+4,825	New	+$270K	0.05%	232

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

L & S Advisors's AERI Position: Q2 2021 in Review

L & S Advisors sold out of Aerie Pharmaceuticals (AERI) in Q2 2021, closing a stake of 12,500 shares — an estimated $223K sold.

L & S Advisors first reported a position in AERI in Q2 2018 and held it in 3 quarters. The position peaked at $326K in Q2 2018. 142 funds tracked by Wall St. Rank hold AERI as of Q2 2021.

L & S Advisors reported no remaining Aerie Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
L & S Advisors sold 12,500 Aerie Pharmaceuticals shares in Q2 2021, an estimated $223K.
L & S Advisors first reported a position in Aerie Pharmaceuticals in Q2 2018 and held it in 3 quarters.
L & S Advisors's Aerie Pharmaceuticals position peaked at $326K in Q2 2018.
142 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2021.

Based on L & S Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.